Rosetta Genomics Ltd. (NASDAQ:ROSG) major shareholder Healthcare Master Fund Sabby purchased 175,828 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were acquired at an average price of $0.42 per share, for a total transaction of $73,847.76. The acquisition was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Rosetta Genomics Ltd. (NASDAQ:ROSG) remained flat at $$0.43 on Wednesday. The company’s stock had a trading volume of 134,499 shares, compared to its average volume of 168,527. Rosetta Genomics Ltd. has a 1-year low of $0.23 and a 1-year high of $5.64. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.10 and a current ratio of 2.10.
ROSG has been the topic of a number of recent research reports. ValuEngine upgraded shares of Rosetta Genomics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Barrington Research downgraded shares of Rosetta Genomics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 18th.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/03/14/healthcare-master-fund-sabby-acquires-175828-shares-of-rosetta-genomics-ltd-rosg-stock.html.
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests-based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.